Magister Pharmaceuticae - MPharm / Neurodegenerative disorders (NDs) are a range of chronic brain disorders that includes
amongst others motor function loss. Parkinson’s disease (PD) is one of the common NDs that
has an insidious onset and diagnosed when dopaminergic neurons in the substantia nigra are
already lost. The loss creates a deficiency of the dopamine (neurotransmitter) thereby causing
neurochemical imbalance resulting in the signs and symptoms of PD. NDs overlap at multiple
levels so some of the symptoms overlap as well. NDs currently have no cure yet and current
drug therapies only improve the quality of life of the patients by targeting the symptoms
mainly. Treatment of PD currently involves different classes of drugs and depending on the
stages of the disease, some drugs can be only used as an adjunct therapy. Anti-oxidants and
monoamine oxidase inhibitors (MAO-I) are part of the treatment options.
| Identifer | oai:union.ndltd.org:netd.ac.za/oai:union.ndltd.org:uwc/oai:etd.uwc.ac.za:11394/7959 |
| Date | January 2020 |
| Creators | Musakwa, Lovetone |
| Contributors | Joubert, Jacques, Malan, Sarel |
| Publisher | University of the Western Cape |
| Source Sets | South African National ETD Portal |
| Language | English |
| Detected Language | English |
| Rights | University of the Western Cape |
Page generated in 0.0019 seconds